Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
scAAV2-P1ND4v2 Gene Therapy for LHON
NCT02161380Phase 1Completed
- Start
- Jul 2014
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, Engineered AAV
- Countries
- 1
01
Overview
Phase 1, open-label trial of scAAV2-P1ND4v2 in Leber hereditary optic neuropathy (LHON) (4 arms). Primary endpoint: Number of Treatment Related Adverse Events at 3 years. Started Jul 2014; status: completed.
02
Drugs
scAAV2-P1ND4v2
03
Conditions
Leber hereditary optic neuropathy (LHON)
Beyond the preview
Go deeper on NCT02161380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02161380.